China Chemical & Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

19.56

P/S

0.74

EPS

1.08

Div Yield, %

3.78%

Shrs. gr., 5y

0.09%

Rev. gr., 5y

2.50%

Revenues

8.57b

+1.40%

Net income

322m

-32.51%

CFO

239m

+43.10%

Dividend

Jul 26, 20240.50003 TWD/sh

Earnings

Mar 10, 2025

Profile

China Chemical & Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. The company provides sexual function supplements; cardiovascular drugs, anti-lipidemia drugs, and peripheral circulation impediment relieving agents; diabetes treatment drugs, adrenocortico steroids, and weight control drugs; and anti-infection drugs, such as antibiotics, antifungal drugs, and anti-viral drugs. It also offers nutritional supplements comprising vitamins, liver toning agents, and electrolyte and calorie preparations; antipyretic, analgesic, and anti-inflammatory medicines; digestive drugs, intestinal improvement agents, and antispasmodics; cough suppressants, antihistamines, and asthma treatment agents; BPH drugs for the urinary system; hypnotic, mental stability, and antidepressant drugs; hematology/oncology drugs; and other general preparations. In addition, the company provides over the counter drugs such as vitamins, external skin care products, cold and cough medicines, anti-inflammatory analgesics, and gastrointestinal drugs; and antibacterial and disinfection medicines. Further, it manufactures animal health products, including drugs for pigs and cattle, companion animal products, poultry drugs, and feed supplements; and offers contract manufacturing services. The company was founded in 1952 and is headquartered in Taipei, Taiwan.

URL

http://www.ccpc.com.tw/

IPO date

Feb 09, 1962

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title TWD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title TWD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	8,574,720 1.40%	8,456,512 6.38%	7,948,998 -2.84%
Cost of revenue	8,437,054	8,087,740	7,537,637
Unusual Expense (Income)
NOPBT	137,666	368,772	411,361
NOPBT Margin	1.61%	4.36%	5.18%
Operating Taxes	67,644	109,402	142,885
Tax Rate	49.14%	29.67%	34.73%
NOPAT	70,022	259,370	268,476
Net income	322,294 -32.51%	477,541 -7.72%	517,508 -7.15%
Dividends	(238,465)	(268,273)	(298,081)
Dividend yield	3.28%	2.69%	4.37%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	1,688,034	1,351,809	1,174,362
Long-term debt	2,065,668	1,912,130	1,974,223
Deferred revenue	313,584
Other long-term liabilities	98,598	105,392	117,634
Net debt	961,779	651,379	(254,548)
Cash flow
Cash from operating activities	239,365	167,272	695,891
CAPEX	(306,061)	(270,974)	(208,356)
Cash from investing activities	(332,436)	(374,611)	(120,872)
Cash from financing activities	(247,143)	(209,400)	(769,295)
FCF	(502,717)	94,265	352,247
Balance
Cash	489,218	852,264	946,092
Long term investments	2,302,705	1,760,296	2,457,041
Excess cash	2,363,187	2,189,734	3,005,683
Stockholders' equity	6,852,209	6,810,004	7,169,931
Invested Capital	8,598,013	8,422,435	7,900,389
ROIC	0.82%	3.18%	3.41%
ROCE	1.24%	3.42%	3.71%
EV
Common stock shares outstanding	298,653	299,535	300,926
Price	24.35 -26.77%	33.25 46.80%	22.65 -4.03%
Market cap	7,272,201 -26.98%	9,959,539 46.12%	6,815,974 -3.68%
EV	8,272,031	10,647,710	6,595,786
EBITDA	451,929	660,590	688,827
EV/EBITDA	18.30	16.12	9.58
Interest	59,538	41,883	35,760
Interest/NOPBT	43.25%	11.36%	8.69%